Sometimes in biotech, the numbers just don't work out the way you need them to. Rezolute Inc. (RZLT) found that out the hard way on Thursday, watching its stock crater nearly 90% after releasing Phase 3 trial results that technically showed improvement—just not enough improvement compared to placebo to matter.
The drama unfolded around the company's sunRIZE study, which tested ersodetug in patients with congenital hyperinsulinism. This is a rare genetic disorder where the pancreas gets overly enthusiastic about pumping out insulin, leading to dangerously low blood sugar levels in infants and children. It's exactly as serious as it sounds.
Trading volume told the story before the details even mattered: 82.25 million shares changed hands compared to an average daily volume of just 1.6 million. Shares fell to $1.23, marking a fresh 52-week low.
The Problem With Placebo
Here's where things get frustrating for Rezolute. The study missed its primary endpoint, which measured changes in weekly hypoglycemia events tracked through self-monitored blood glucose readings. At the top dose of 10 mg/kg, ersodetug delivered an approximate 45% reduction in hypoglycemia events. That sounds impressive until you learn the placebo group improved by 40%.
That razor-thin difference wasn't statistically significant, and in clinical trials, statistical significance is everything. You either clear the bar or you don't.
The key secondary endpoint didn't fare any better. This one assessed the change in average daily time spent in hypoglycemia using continuous glucose monitoring. At the 10 mg/kg dose, ersodetug showed roughly a 25% reduction in time spent hypoglycemic. Meanwhile, the placebo group's time in hypoglycemia actually increased by approximately 5%. Better relative performance, sure, but still not statistically significant enough to declare victory.
The dosing regimen involved 5 mg/kg and 10 mg/kg administered every other week for three doses, then every four weeks over the remaining 24-week treatment period. The good news? Ersodetug hit target drug concentrations across all age groups studied.
Safety Data Provides Some Comfort
If there's a silver lining here, it's that the safety observations were generally favorable. The company believes the data supports safe use of ersodetug in both pediatric and adult patients, which matters when you're talking about treating children with a rare genetic condition.
That said, two study participants did experience serious hypersensitivity reactions that forced them to discontinue the drug early. Not ideal, but in the context of rare disease trials, safety issues in a small number of patients don't automatically doom a program.
Rezolute still has another shot on goal. The company's Phase 3 upLIFT study for tumor-related hyperinsulinism remains ongoing, with topline results expected in the second half of 2026. Whether investors have the patience to wait that long after Thursday's billion-dollar wipeout is another question entirely.
